US Department of Justice has officially reclassified cannabis as less dangerous

Policy & legal process

• Change currently applies only to FDA-covered or state-licensed medical cannabis products; broader rescheduling is subject to a future hearing.
• Debate over presidential power: some claim reclassification is “just a pen stroke”; others argue it required multi‑year scientific and regulatory review and DEA cooperation.
• Disagreement on credit: some say the prior administration merely finished a process initiated earlier; others say it canceled earlier work and restarted it.
• Concern about ruling by executive order vs. going through Congress and agencies; some see executive shortcuts as undemocratic even if they like the outcome.
• Question raised whether DEA, not DOJ, must formally reclassify, and how this interacts with existing schedules.

Party politics & criminal justice

• Many see prior inaction (by multiple presidents) as political calculation: fear of alienating unions, law enforcement, or specific voter blocs.
• Some note major declines in federal marijuana prosecutions and mass pardons for simple possession, but emphasize most enforcement is at the state level.
• Private prison and police incentives are cited as reasons for long‑standing opposition to reform.
• Disagreement whether “legalize it” is an electoral winner: some see it as low‑risk, high‑reward; others think it matters only at the margins or has lost salience as more states legalize.

Health impacts & mental health

• Strong call for a “grown‑up” discussion: cannabis can help some but clearly harms others, especially heavy users and people with depression or neurodivergence.
• Multiple commenters report cannabis worsening or prolonging anxiety, depression, or psychosis‑like symptoms; others describe substantial relief of pain, mood, and autistic traits with specific strains.
• Consensus that cannabis is not a universal treatment for mental health; evidence cited that benefits are limited for conditions like depression and anxiety, and that cannabis use disorder is real.
• Concerns over very high‑THC products, rapidly rising tolerance, and adolescent brain development.
• Frequent comparison to alcohol and nicotine: many argue current policy is inconsistent given alcohol’s known high harm, but agree none of these drugs are “safe.”

Addiction, regulation & freedoms

• Broader discussion about “vulnerable minorities” who cannot use drugs, gambling, or loot‑box mechanics responsibly; tension between personal freedom and corporate exploitation.
• Some argue prohibition has clearly failed (esp. in hard drugs), favoring regulation and social support instead; others note that completely unregulated access (e.g., opiates, gambling apps) has also been disastrous.
• Debate over 12‑step programs: some dismiss them as religious; others defend them as flexible, effective, and not inherently sectarian.
• Philosophical split: one side insists adults should be free to consume any plant they grow; others point to poppies, invasive species, or asbestos as counterexamples where regulation is justified.

Everyday impacts & social norms

• Several support legalization but dislike pervasive cannabis odor, especially in dense cities or shared housing; some advocate bans on all public smoking/vaping.
• Others emphasize respect for non‑users: fine to use privately, but not to impose smoke or smell on others.
• Banking access and taxation are seen as next practical steps, with ideas to channel tax revenue into treatment and mental health services, though past examples (e.g., state marijuana or lottery revenues) are viewed skeptically.